Else, Monica <br/><br/>
Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.  [electronic resource] 

 -  British journal of haematology  Nov 2012 
 - 322-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.12036  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Disease Progression<br/>Female<br/>Humans<br/>Lymphoma, B-Cell, Marginal Zone--drug therapy<br/>Male<br/>Middle Aged<br/>Rituximab<br/>Splenic Neoplasms--drug therapy<br/>Treatment Outcome